Western blotting market seen reaching $2.14 billion by 2030

The Business Research Company says the global western blotting market will grow from $1.39 billion in 2025 to $1.52 billion in 2026, driven by demand for protein analysis, diagnostics and research. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest through 2030.

Why it matters: - Western blotting is a core tool for protein detection in life sciences, diagnostics and biomedical research. - Rising demand for biomarker-based diagnostics, proteomics and clinical studies is expanding use of the technique. - HIV diagnosis is one cited driver because western blotting supports confirmation testing and early treatment decisions.

What happened: - The Business Research Company released a western blotting market report on Sept. 3, 2026. - The report estimates the market will rise from $1.39 billion in 2025 to $1.52 billion in 2026. - The report projects the market will reach $2.14 billion by 2030. - The company published a free sample of the report and the full report.

The details: - The report puts 2026 growth at a 9.2% compound annual rate. - It forecasts a 9.0% compound annual growth rate through 2030. - Market growth is tied to life science research, protein analysis in diagnostics, academic funding, antibody-based assays and pharmaceutical research investment. - Expected growth drivers include biomarker-based diagnostics, proteomics, laboratory automation, high-throughput protein analysis and clinical use. - Key trends include automated western blot systems, sensitive protein detection, ready-to-use reagent kits, digital imaging tools and a push for reproducibility and standardization. - Western blotting separates proteins by gel electrophoresis, transfers them to a membrane and uses antibodies to identify target proteins. - The technique is used to study protein expression levels, molecular weights and post-translational modifications. - The report says HIV prevalence is helping drive demand for western blotting. - UK government data cited in the release showed HIV diagnoses rose 46% in 2023 to 6,402 from 4,379 in 2022. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a market shifting from manual protein analysis toward more automated and standardized workflows. - Growing HIV diagnoses and broader biomarker testing needs suggest western blotting remains relevant even as newer tools expand in diagnostics. - Regional momentum appears tied to research spending and healthcare investment, not just clinical demand.

What's next: - The report expects adoption to accelerate around automated systems, digital analysis and higher-throughput workflows. - Asia-Pacific’s growth could narrow the gap with North America if research and healthcare investment continue to rise. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics and tables.

The bottom line: - Western blotting is moving from a mature lab method to a more automated, data-driven market with steady global expansion.